July twenty _ eighth$Pfizer Inc (PFE.US) $In the first half of 2022, total revenue was US $53.4 billion, up 60% from the same period last year; net profit was US $17.769 billion, up 70% from the same period last year; and R & D investment was US $5.116 billion, up 21% from the same period last year.

Pfizer Inc's current business is mainly focused on vaccines, oncology, cardiovascular, immunity, rare diseases and other areas. Specifically,MRNA vaccine Comirnaty (US $22.075 billion, + 95%) and COVID-19 oral drug Paxlovid (US $9.585 billion)The performance is bright, the growth is strong, contributing more than half of the sales.

Mature innovative drug products such as Eliquis (Apexaban, $3.537 billion, + 13%), Prevnar family ($2.994 billion, + 19%), rare heart disease drug Vyndaqel/Vyndamax ($1.164 billion, + 22%) and Inlyta ($508 million, + 4%) are still important factors driving performance growth.

Sales of Xtandi, a prostate cancer drug, and Ibrance, a breast cancer drug, fell slightly, to 2 per cent and 4 per cent, respectively, to $802 million in the first half of the year, down 29 per cent from a year earlier, with poor market performance.

Comirnaty's market share gradually expanded in the first half of 2022, with more than 3.6 billion doses of vaccine distributed to 180 countries and regions, with total sales of US $22.075 billion (+ 95%). But in the second quarter, the vaccine earned only $8.848 billion. This is mainly due to a decrease in the number of vaccinations in the United States and a sharp drop in sales (- 47%). However, in June this year, Pfizer Inc and the US government reached a new agreement to provide an additional 105 million doses of COVID-19 vaccine, worth as much as US $3.2 billion.

For Comirnaty, Pfizer Inc and BioNTech are currently working hard to expand their applicable population and strengthen the use of needles in various countries. At the same time, they have also developed bivalent vaccine candidates for BA.1 and BA.4/BA.5 to continuously enhance their ability to fight against mutants.

COVID-19 oral drug Paxlovid earned 9.585 billion US dollars in 2022H1, of which Q2 earned 8.115 billion US dollars, which contributed a lot. This benefits from the wide popularity of the product in the United States and the expansion of international market access.

Pfizer Inc is preparing to launch two Paxlovid clinical studies at 2022H2: an EPIC-IC study for immunodeficient people, with plans to recruit 150patients, and an EPIC-Hos study for hospitalized patients, with plans to recruit 279patients.

In addition, clinical studies for pregnant women are under way. For high-risk people, Pfizer Inc has submitted a listing application to FDA based on EPIC-HR research data, and the PDUFA date is 2023Q1. In the future, Pfizer Inc will also consider including COVID-19 's sequelae (Long COVID) into clinical research.

In 2022, Pfizer Inc's income guidance will remain at US $98 billion-US $102 billion, with Comirnaty's expected income of US $32 billion and Paxlovid of US $22 billion.